What is NeoGenomics's D&A?

NeoGenomics (NEO) reported D&A of $8.78M in Q1 2026.

How has NeoGenomics's D&A changed year-over-year?

NeoGenomics's D&A decreased by 6.3% year-over-year, from $9.37M to $8.78M.

What is the long-term trend for NeoGenomics's D&A?

Over 4 years (2021 to 2025), NeoGenomics's D&A has grown at a 4.5% compound annual growth rate (CAGR), from $30.19M to $36.07M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

NeoGenomics NEO D&A

D&A at other companies

Labcorp HoldingsLH

$173.3M+3.9%

Quest DiagnosticsDGX

$147M+5.0%

Personalis, Inc.PSNL

$2.37M-8.3%

Guardant HealthGH

$9.44M-7.8%

Natera, Inc.NTRA

$14.52M+57.2%

GeneDx HoldingsWGS

$6.81M+19.9%

Segments

By segment

See full

Reportable Segment$7.63M-8.7%

Other financials

Income statement

See full

Revenue$186.7M+11.1%

Gross profit$80.9M+10.4%

Operating income-$18.2M+34.4%

Net income-$17.1M+34.0%

EPS (diluted)-$0.13+35.0%

Balance sheet

See full

Cash & equivalents$146.1M-57.8%

Total debt$66.3M+5.3%

Total equity$828.8M-6.7%

Total assets$1.3B-15.9%

Cash flow

See full

Operating cash flow-$8.1M+67.9%

CapEx$5.0M+11.1%

Free cash flow-$13.1M+56.0%

Valuation

See full

Market cap$1.68B-21.0%

Enterprise value$1.6B-5.6%

P/S2.3×-0.9×

Profitability

See full

Gross margin43.2%-1.1pp

Operating margin-14.2%+1.1pp

Net margin-13.3%+2.4pp

FCF margin-4.9%—

Returns & leverage

See full

Return on equity-11.6%+6.2pp

Debt / equity0.1×0.0×

Current ratio4.4×+2.4×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: NeoGenomics’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about NeoGenomics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NeoGenomics's D&A?: NeoGenomics (NEO) reported D&A of $8.78M in Q1 2026.
How has NeoGenomics's D&A changed year-over-year?: NeoGenomics's D&A decreased by 6.3% year-over-year, from $9.37M to $8.78M.
What is the long-term trend for NeoGenomics's D&A?: Over 4 years (2021 to 2025), NeoGenomics's D&A has grown at a 4.5% compound annual growth rate (CAGR), from $30.19M to $36.07M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.